Mohammad Daniel El Basha

Mentor: Dr. Wesley Bolch
College of Engineering
"My interest in biomedical research stems from the desire to make a direct impact on the lives and well-being of others. I have always had a passion for medicine and technology along with the innovations they bring. Many diseases and ailments have yet to addressed with a cure or even proper treatment methods. Through my current project I will be able to address treatment options for patients with Age-related macular degeneration (AMD), one of the leading causes of blindness worldwide."


Biomedical Engineering



Research Interests

  • CT Dosimetry
  • Computational/Physical Phantom Construction
  • Digital Disign

Academic Awards

  • AICE Scholar 2015
  • Florida Bright Futures Scholarship
  • Goals for Tomorrow Scholarship 2016
  • University Scholars Program Scholarship 2016


  • Society of Hispanic Professional Engineers



Hobbies and Interests

  • Taekwondo
  • Learning Languages
  • Chess
  • Gardening

Research Description

Dose to Non-Targeted Tissues of Myopic Eyes during Stereotactic Radiosurgery for Macular Degeneration
Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly population of industrialized nations. Advanced stages of AMD that lead to vision loss come in both the wet and dry forms, although the wet form accounts for almost 90% of the vision loss in the advanced stages. Although radiation delivery devices for the treatment of AMD are being developed, which noninvasively delivers a one-time single fraction therapeutic dose to the macula for eye shapes in 20x20 patients. What has not yet been addressed are variations in eye shape in near-sighted patients. The purpose of this project will be to create a series of myopic eye models and perform treatment scenarios subjecting the eye models to radiation treatments with beam polar entry angles from 18-34 degrees in 2 degree increments. There is concern that the distortion of the eye seen in myopia could lead to changes in dose to the non-targeted tissues, and therefore the myopic eye models will be compared to the work currently being done in the ALRADS lab group with emmetropic eyes to see if there are indeed significant dose variations, a serious issue as estimates show that approximately 30% of all Americans have myopic eyes.